PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Human Menopausal Gonadotropin→

Human Menopausal Gonadotropin PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
61489-71-2
Molecular formula
Not available
Molecular weight
Not available
Drug class
Gonadotropin preparationurinary human FSH/LH (menotrophin)
Mechanism of action
Provides follicle-stimulating hormone (FSH) and luteinising hormone (LH) activity. FSH stimulates ovarian follicular development and granulosa-cell function, while LH supports theca-cell androgen production and, with appropriate stimulation, ovulation; in men, gonadotropin activity supports spermatogenesis through Sertoli and Leydig cell signalling.
Indications / reported uses
  • Controlled ovarian stimulation for assisted reproductive technology and ovulation induction in women with anovulation or inadequate gonadotropin response.
  • Stimulation of spermatogenesis in selected men with hypogonadotropic hypogonadism, usually in combination with hCG.

Sources: https://www.medicines.org.uk/emc/product/4595/smpc · https://www.ema.europa.eu/en/medicines/human/EPAR/menopur · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Human Menopausal Gonadotropin PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Human Menopausal Gonadotropin Permitted Daily Exposure (PDE) report (the Human Menopausal Gonadotropin PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Human Menopausal Gonadotropin Occupational Exposure Limit (OEL) report (the Human Menopausal Gonadotropin OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.